 would meet the suggested threshold of a
7.5% 10-year risk. It is noteworthy that speciÔ¨Åc low-density
lipoprotein targets have never been validated in the PAD population, who commonly demonstrate a phenotype of dyslipidemia (low high-density lipoprotein, elevated triglycerides),
which contrasts with typical patients with isolated coronary
artery disease. Statin therapy has also improved pain-free
walking time in small studies of patients with IC.72,